The science of love

Houston entrepreneur pivots from DNA dating to a compatibility program for couples

Brittany Barreto has expanded her DNA dating technology to a compatibility company named We Have Chemistry. Courtesy of WeHaveChemistry

As Brittany Barreto was developing and promoting her DNA-based dating app, Pheramor, that can establish compatibility in prospective couples using a certain string of genetics, she made some couples very jealous. While not single, they wanted to know the compatibility they have with their partner.

"For every single we connected with through Pheramor, there were at least three couples that wanted to complete the DNA swab to find out their compatibility," she says in a news release.

Now, Barreto and her team, which now includes acclaimed relationship expert Laura Berman, have developed WeHaveChemistry, a series of tests and DNA analysis that can give couples a look at their compatibility. And, WeHaveChemistry has taken it a step further to include more than just DNA in the report.

"The team is very excited about WeHaveChemistry," says Barreto in the release. "We've done our research and carefully crafted two reports: the socioemotional analysis and the DNA report. All couples will receive both reports to analyze their physical and emotional chemistry—which we refer to as their 'Love Alchemy."

The results aren't categorized as good or bad, and there's no score determined for couples — the findings are meant to be used to enhance the relationship and as a guide for navigating the trials and tribulations that often come with monogamy.

"The most important way for couples to ensure that their relationship stays strong is to both play to their strengths and to be honest and curious about their areas for growth," says Berman in the release. "We all have areas where we need to stretch a little, both as partners and as people, and couples can apply the findings of the SEA to their relationships and begin growing right away. In addition, the SEA identifies where we are strongest, what we should celebrate and honor, and the areas which we can rely on as a firm foundation when times get tough."

The process goes as follows:

  • Couples complete the DNA kit.
  • Each person takes the socioemotional analysis quiz, which analyzes emotional intimacy, physical connection, purpose, and future vision. The quiz will identify the person's strengths.
  • Each person receive their DNA report, which assesses sexual chemistry based on genetics.
  • The two aspects — the DNA report and the quiz results — are combined to predict and guide chemistry.

The way genetics affects attraction is completely subconscious and instinctual, dating back to primitive times.

"The science behind attraction based on your DNA is that people are attracted to one another when their immune systems are different — opposites attract is biologically true," Barreto says in a previous InnovationMap article. "When we were cavewomen and cavemen, we didn't know who was our uncle and who was our cousin, so we used our nose to figure out who is genetically diverse compared to us. If you're genetically diverse, then you're probably not my relative, and therefore we'd have healthier children."

Of course, nowadays, there are many more factors that go into compatibility and both Pheramor and WeHaveChemistry have included that in their assessments.

Swabbing for love

Courtesy of WeHaveChemistry

The DNA kit has swabs and information for two people and is sent through the mail.




Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted